Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

MicroRNA Strongly Linked to Acute Myeloid Leukemia Risk and Recovery

By BiotechDaily International staff writers
Posted on 29 May 2013
Image: Senior author Dr. Clara D. Bloomfield (Photo courtesy of Ohio State University).
Image: Senior author Dr. Clara D. Bloomfield (Photo courtesy of Ohio State University).
Overexpression of a specific microRNA (miRNA) in patients suffering from cytogenetically normal (CN) acute myeloid leukemia (AML) has been linked to lower complete remission rate as well as to shorter disease-free and overall survival.

MicroRNAs (miRNAs) are snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.

Investigators at Ohio State University (Columbus, USA) measured miRNA levels and expression profiles in the blood and bone marrow of obtained from 363 patients with primary CN-AML. The test population comprised 153 patients under age 60 and 210 aged 60 and over.

Results published in the May 6, 2013, online edition of the Journal of Clinical Oncology strongly linked microRNA-155 (miR-155) to the severity of the disease. Patients with high miR-155 expression were found to be about 50% less likely to achieve complete remission and to have a 60% increase in the risk of death compared to patients with low miR-155 expression.

Although high miR-155 expression was not associated with a distinct miRNA expression profile, it was associated with a gene expression profile enriched for genes involved in cellular mechanisms deregulated in AML. These mechanisms included apoptosis, nuclear factor-kappaB activation, and inflammation.

Senior author Dr. Clara D. Bloomfield, professor of medicine at Ohio State University, said, “Overall, our findings indicate that miR-155 expression is a strong and independent prognostic marker in CN-AML, and they provide clinical validation of data from preclinical models that support a crucial role of miR-155 in leukemia.”

The development of drugs with antagonistic activity toward microRNAs may provide the opportunity for future therapeutic targeting of miR-155 in AML.

Related Links:
Ohio State University



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.